Krystal Biotech Inc (KRYS)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 12,897 | -139,975 | -69,570 | -32,167 | -19,088 |
| Revenue | US$ in thousands | 55,764 | 498 | — | — | — |
| Pretax margin | 23.13% | -28,107.43% | — | — | — |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $12,897K ÷ $55,764K
= 23.13%
Based on the data provided, the pretax margin of Krystal Biotech Inc has shown a significant improvement from -28,107.43% in 2022 to 23.13% in 2023. This positive trend indicates that the company's pre-tax earnings relative to its total revenue have increased, reflecting improved operational efficiency and profitability. However, the absence of data for the years 2021, 2020, and 2019 limits the ability to assess the pretax margin trajectory over a longer period. It is important for investors and stakeholders to monitor the company's pretax margin performance consistently to evaluate its financial health and sustainability.
Peer comparison
Dec 31, 2023